A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.
Males or females aged ≥18 years at Screening. [+14]
Treatment with systemic anticancer therapy or an investigational agent within 2... [+20]